Robeco Institutional Asset Management B.V. Sells 20,389 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Robeco Institutional Asset Management B.V. trimmed its IDEXX stake by 9.9%, selling 20,389 shares and now owns 186,127 shares (about 0.23% of the company) valued at roughly $125.92 million.
• Insiders sold a total of 45,957 shares (~$29.86 million) during the quarter, including EVP Michael G. Erickson and EVP Nimrata Hunt, leaving corporate insiders with about 0.79% ownership.
• IDEXX recently beat quarterly EPS estimates and set FY2026 guidance of $14.29–$14.80, while the stock trades near $563 with a 12‑month range of $375–$770 and a consensus rating of "Moderate Buy" (average price target $772.22).

Robeco Institutional Asset Management B.V. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 186,127 shares of the company's stock after selling 20,389 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.23% of IDEXX Laboratories worth $125,920,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blalock Williams LLC bought a new position in IDEXX Laboratories in the third quarter valued at approximately $590,000. Nordea Investment Management AB boosted its position in shares of IDEXX Laboratories by 114.1% during the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company's stock worth $11,283,000 after purchasing an additional 8,845 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company's stock worth $38,477,000 after purchasing an additional 3,820 shares in the last quarter. Beacon Investment Advisory Services Inc. boosted its position in shares of IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company's stock worth $42,588,000 after purchasing an additional 6,710 shares in the last quarter. Finally, Mediolanum International Funds Ltd boosted its position in shares of IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company's stock worth $24,441,000 after purchasing an additional 4,909 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the firm's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 over the last quarter. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $563.00 on Monday. IDEXX Laboratories, Inc. has a 12 month low of $375.05 and a 12 month high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company's fifty day simple moving average is $607.41 and its 200 day simple moving average is $656.92. The firm has a market cap of $44.72 billion, a price-to-earnings ratio of 43.08, a PEG ratio of 3.42 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the business posted $2.53 earnings per share. The firm's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen cut shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Weiss Ratings cut shares of IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. UBS Group reduced their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. Finally, BTIG Research reduced their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $772.22.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.